| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1010195790 |
| P356 | DOI | 10.1186/1471-2431-12-8 |
| P932 | PMC publication ID | 3335368 |
| P698 | PubMed publication ID | 22264311 |
| P5875 | ResearchGate publication ID | 51993285 |
| P50 | author | Antonio Clavenna | Q42633171 |
| P2093 | author name string | Maurizio Bonati | |
| Filomena Fortinguerra | |||
| P2860 | cites work | Paediatric clinical pharmacology: at the beginning of a new era. | Q53171213 |
| Recommendations for prevention of neonatal ophthalmia. Infectious Diseases and Immunization Committee, Canadian Paediatric Society | Q71821226 | ||
| Brazilian guidelines proposal for screening and treatment of retinopathy of prematurity (ROP) | Q33312263 | ||
| Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. | Q33322288 | ||
| Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity: a pilot study | Q33351259 | ||
| Emerging treatments for retinopathy of prematurity | Q33431318 | ||
| Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs | Q33812926 | ||
| Antiangiogenic drugs in the management of ocular diseases: Focus on antivascular endothelial growth factor | Q33819829 | ||
| Topical therapies and medications in the pediatric patient | Q34003459 | ||
| Management of ophthalmic disease in general practice | Q34371858 | ||
| Pediatric use of topical ophthalmic drugs. | Q35856716 | ||
| Topical ophthalmic drugs and the pediatric patient. | Q35870074 | ||
| Systemic adverse effects of topical ocular treatments | Q36166092 | ||
| Pharmacologic management of glaucoma in childhood | Q36779645 | ||
| European paediatric research and children's therapeutic needs. A trial review | Q37167674 | ||
| Conducting clinical trials in pediatrics | Q37356870 | ||
| The safety and efficacy of glaucoma medication in the pediatric population | Q37391628 | ||
| Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition | Q37448448 | ||
| Concentration of vascular endothelial growth factor in aqueous humor of eyes with advanced retinopathy of prematurity before and after intravitreal injection of bevacizumab | Q37476611 | ||
| EMEA and the new pharmaceutical procedures for Europe. European Medicines Evaluation Agency | Q41004567 | ||
| Regulation of drugs for children in Europe | Q42824007 | ||
| Is it time for a European formulary of paediatric medicines? | Q43028598 | ||
| Ocular medications in children | Q43534493 | ||
| Prevalence of eye disease in early childhood and associated factors: findings from the millennium cohort study | Q43606556 | ||
| Systemic side effects of ophthalmic drops | Q44767600 | ||
| Can we get the necessary clinical trials in children and avoid the unnecessary ones? | Q45971835 | ||
| Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity | Q46720743 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | eye disease | Q3041498 |
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 8 | |
| P577 | publication date | 2012-01-20 | |
| P1433 | published in | BMC Pediatrics | Q15750892 |
| P1476 | title | Ocular medicines in children: the regulatory situation related to clinical research | |
| P478 | volume | 12 |
Search more.